Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Novocure Ltd Ord Sh (NQ: NVCR )

17.44 -0.21 (-1.19%)
Streaming Delayed Price Updated: 4:00 PM EST, Nov 8, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Novocure Ltd Ord Sh

< Previous 1 2 3 4 5 6 7 8 9
...
17 18 Next >
INVESTIGATION REMINDER: The Schall Law Firm Announces it is Investigating Claims Against NovoCure Limited and Encourages Investors with Losses to Contact the Firm
From The Schall Law Firm
Via Business Wire
These 2 Nasdaq Stocks Are Plunging. Here's Why
Tuesday brought optimism to the stock market overall, but not for these companies. 
Via The Motley Fool
Dow Falls Over 100 Points; Hoth Therapeutics Shares Spike Higher
U.S. stocks traded mixed toward the end of trading, with Dow Jones dropping over 100 points on Tuesday. The Dow traded down 0.36% to 33,440.78 while the NASDAQ rose 0.09% to 13,241.04. The S&P 500,... 
Via Benzinga
INVESTIGATION ALERT: The Schall Law Firm Announces it is Investigating Claims Against NovoCure Limited and Encourages Investors with Losses to Contact the Firm
From The Schall Law Firm
Via Business Wire
The Latest Analyst Ratings for NovoCure
Via Benzinga
Why NovoCure Stock Is Crashing Today
Analysts weren't wowed by the company's late-stage data. 
Via The Motley Fool
Stocks That Hit 52-Week Lows On Tuesday
  On Tuesday, 69 stocks hit new 52-week lows. 
Via Benzinga
Stocks Mixed As VIX Extends Lows
Stocks are struggling for direction midday. 
Via Talk Markets
Novocure's Cancer Treating Electric Fields Improves Survival In Lung Cancer Patients, But Stock Tumbles On Remaining Doubts
Via Benzinga
NovoCure's Return On Capital Employed Overview
Via Benzinga
4 Analysts Have This to Say About NovoCure
Via Benzinga
Should You Buy Novocure Stock Right Now?
Most Wall Street analysts think this stock will skyrocket. They could be right. 
Via The Motley Fool
12 Health Care Stocks Moving In Tuesday's Intraday Session
Via Benzinga
Why THOR Industries Shares Are Trading Higher By 15%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session
Gainers Recruiter.com Group, Inc. (NASDAQ: RCRT) shares jumped 114% to $0.41. Recruiter.com signed a definitive agreement for planned purchase of fintech assets of GoLogiq. 
Via Benzinga
Nasdaq Edges Higher; Joann Shares Plummet
U.S. stocks traded mixed midway through trading, with Nasdaq Composite turning higher on Tuesday. The Dow traded down 0.08% to 33,534.50 while the NASDAQ rose 0.27% to 13,265.27. The S&P 500, also... 
Via Benzinga
NovoCure (NVCR) Q1 2023 Earnings Call Transcript
NVCR earnings call for the period ending March 31, 2023. 
Via The Motley Fool
Novocure Stock Dips As Q1 Earnings Miss Estimates, Higher Costs Hurt Bottom Line
Via Benzinga
Coinbase, Blue Bird, Tingo Group And Other Big Stocks Moving Lower On Tuesday
U.S. stocks traded mixed, with the Nasdaq Composite rising around 0.2% on Tuesday. Here are some big stocks recording losses in today’s session. 
Via Benzinga
Novocure Crashes Almost 30% As Critics Question Its 'Profound' Impact In Lung Cancer Treatment
Novocure said its device, Optune, extended overall survival by more than three months for some lung cancer patients. 
Via Investor's Business Daily
Dow Drops 50 Points; J.M. Smucker Earnings Top Views
U.S. stocks traded lower this morning, with Dow Jones dropping around 50 points on Monday. The Dow traded down 0.16% to 33,509.87 while the NASDAQ fell 0.19% to 13,203.91. The S&P 500, also fell,... 
Via Benzinga
Zai Lab and Novocure Announce LUNAR Phase 3 Clinical Trial Demonstrates Statistically Significant and Clinically Meaningful Extension in Overall Survival for Patients with Metastatic Non-Small Cell Lung Cancer After Platinum-Based Therapies
From Zai Lab Limited
Via GlobeNewswire
NovoCure: Q1 Earnings Insights
Via Benzinga
LUNAR Phase 3 Clinical Trial Demonstrates Statistically Significant and Clinically Meaningful Extension in Overall Survival for Patients with Metastatic Non-Small Cell Lung Cancer After Platinum-Based Therapies
From Novocure
Via Business Wire
Novocure Pledges $3 Million to Conquer Cancer®, the ASCO Foundation, to Support Cancer Research and Education
From Novocure
Via Business Wire
3 No-Brainer Stocks to Buy for Under $100 Right Now
These stocks might not remain under $100 for too much longer. 
Via The Motley Fool
Benzinga's Top Ratings Upgrades, Downgrades For May 16, 2023
Via Benzinga
Novocure Reports First Quarter 2023 Financial Results
From Novocure
Via Business Wire
The 3 Most Promising Healthcare Tech Stocks for April 2023
The best healthcare tech stocks provide investors with impressive upside potential, while promising to improve the healthcare sector. 
Via InvestorPlace
Novocure Announces Presentation of Results of the LUNAR Phase 3 Clinical Trial in Non-Small Cell Lung Cancer at 2023 American Society of Clinical Oncology (ASCO) Annual Meeting
From Novocure
Via Business Wire
Novocure Announces 27 Presentations, Including Real-World Evidence and Preclinical Research, at American Association for Cancer Research (AACR) Annual Meeting 2023
From Novocure
Via Business Wire
< Previous 1 2 3 4 5 6 7 8 9
...
17 18 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.